Other Events · Jun 5, 2026

Edesa Biotech, Inc. reported favorable exploratory data for its anti-TLR4 monoclonal antibody, paridiprubart, in…

EDSAEdesa Biotech, Inc.

Edesa Biotech, Inc. reported favorable exploratory data for its anti-TLR4 monoclonal antibody, paridiprubart, in patients with acute kidney injury (AKI) and respiratory distress. In a cohort of 101 patients, paridiprubart plus standard of care was associated with a 32% relative reduction in 28-day mortality (33% vs. 49% for placebo) and a 23% relative reduction in the MAKE30 composite endpoint (41% vs. 53% for placebo).